Sign In

Login

Password

Forgot Password ? Sign Up

Survie sans progression (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Survie sans progression" in French language version.

refsWebsite
Global rank French rank
7doi.org
2nd place
3rd place
5nih.gov
4th place
12th place
2semanticscholar.org
11th place
325th place
1cancer.gov
1,684th place
6,412th place
1issn.org
57th place
4th place
1sciencedirect.com
149th place
80th place
1fda.gov
447th place
1,409th place

cancer.gov

doi.org

dx.doi.org

  • E. D. Saad et A. Katz, « Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined », Annals of Oncology, vol. 20, no 3,‎ , p. 460–464 (ISSN 0923-7534, DOI 10.1093/annonc/mdn670, lire en ligne, consulté le )
  • « Recommendations for the assessment of progression in randomised cancer treatment trials », Eur. J. Cancer, vol. 45, no 2,‎ , p. 281–9 (PMID 19097775, DOI 10.1016/j.ejca.2008.10.042)
  • « Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture », JAMA Otolaryngol Head Neck Surg, vol. 140, no 12,‎ , p. 1225–1236 (PMID 25068501, DOI 10.1001/jamaoto.2014.1570)
  • « Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016 », JAMA Netw Open, vol. 3, no 11,‎ , e2024406 (PMID 33170262, PMCID 7656288, DOI 10.1001/jamanetworkopen.2020.24406)
  • « Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021 », Journal of Clinical Oncology, vol. 40, no 35,‎ , p. 4095–4106 (PMID 35921606, DOI 10.1200/JCO.22.00535, S2CID 251317641)
  • Booth et Eisenhauer, « Progression-Free Survival: Meaningful or Simply Measurable? », Journal of Clinical Oncology, vol. 30, no 10,‎ , p. 1030–1033 (PMID 22370321, DOI 10.1200/JCO.2011.38.7571)
  • Basler, « Utility of the McNamara fallacy », BMJ, vol. 339,‎ , b3141 (DOI 10.1136/bmj.b3141, S2CID 71916631)

fda.gov

issn.org

portal.issn.org

  • E. D. Saad et A. Katz, « Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined », Annals of Oncology, vol. 20, no 3,‎ , p. 460–464 (ISSN 0923-7534, DOI 10.1093/annonc/mdn670, lire en ligne, consulté le )

nih.gov

ncbi.nlm.nih.gov

  • « Recommendations for the assessment of progression in randomised cancer treatment trials », Eur. J. Cancer, vol. 45, no 2,‎ , p. 281–9 (PMID 19097775, DOI 10.1016/j.ejca.2008.10.042)
  • « Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture », JAMA Otolaryngol Head Neck Surg, vol. 140, no 12,‎ , p. 1225–1236 (PMID 25068501, DOI 10.1001/jamaoto.2014.1570)
  • « Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016 », JAMA Netw Open, vol. 3, no 11,‎ , e2024406 (PMID 33170262, PMCID 7656288, DOI 10.1001/jamanetworkopen.2020.24406)
  • « Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021 », Journal of Clinical Oncology, vol. 40, no 35,‎ , p. 4095–4106 (PMID 35921606, DOI 10.1200/JCO.22.00535, S2CID 251317641)
  • Booth et Eisenhauer, « Progression-Free Survival: Meaningful or Simply Measurable? », Journal of Clinical Oncology, vol. 30, no 10,‎ , p. 1030–1033 (PMID 22370321, DOI 10.1200/JCO.2011.38.7571)

sciencedirect.com

  • E. D. Saad et A. Katz, « Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined », Annals of Oncology, vol. 20, no 3,‎ , p. 460–464 (ISSN 0923-7534, DOI 10.1093/annonc/mdn670, lire en ligne, consulté le )

semanticscholar.org

api.semanticscholar.org

  • « Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021 », Journal of Clinical Oncology, vol. 40, no 35,‎ , p. 4095–4106 (PMID 35921606, DOI 10.1200/JCO.22.00535, S2CID 251317641)
  • Basler, « Utility of the McNamara fallacy », BMJ, vol. 339,‎ , b3141 (DOI 10.1136/bmj.b3141, S2CID 71916631)